[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graft-rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graft-rejection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,72,91,116,145,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100065731","long-term-evaluation-and-follow-up-care-of-patients-treated-with-stem-cell-transplants-100065731",false,"NCT00106925","Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","Long-Term Evaluation and Follow Up Care of Patients Treated With Allogeneic Stem Cell Transplants","* INCLUSION CRITERIA-TRANSPLANT RECIPIENTS:\n\nPatients surviving three years or more from date of first stem cell transplant who have been treated.\n\n-With an experimental allogeneic stem cell transplant on a NHLBI HB protocol\n\nOr\n\n-With a standard of care allogeneic stem cell transplant on an NHLBI protocol\n\nOr\n\n-Selectively, when the allogenic transplant was conducted outside the NIH, but the subject has a special condition of interest to the research team\n\nAge greater than or equal to 7 years old and age less than or equal to 80\n\nFor adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.\n\nEXCLUSION CRITERIA-STEM CELL TRANSPLANT RECIPIENTS:\n\nNone, all patients meeting the inclusion criteria will be eligible",true,"ALL","7 Years","80 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant.\n\nPatients between 10 and 80 years of age who received a donor stem cell transplant at the NIH Clinical Center under an NHLBI protocol may be eligible for this study. Candidates must have had their first transplant at least 3 years before entering the current study.\n\nParticipants are generally seen in the clinic every 12 months for some or all of the following procedures:\n\n* Periodic physical examinations, eye examinations, and blood and urine tests.\n* Bone marrow aspiration and biopsy: A sample of bone marrow is obtained for microscopic examination. The patient is given local anesthesia or conscious sedation. An area of the hipbone is numbed, a thin needle is inserted through the skin into the bone, and a small amount of marrow is withdrawn.\n* Tissue biopsy: A small piece of tissue or tumor is obtained for microscopic examination. Depending on the site of the biopsy, the tissue may be removed using a cookie cutter-like \"punch\" instrument, a needle, or a knife. The area is numbed and the tissue is removed with the appropriate tool.\n* Imaging tests to visualize organs, tissues, and cellular activity in specific tissues. For these tests, the patient lies on a table that slides into the scanner. They may include the following:\n\n  1. Nuclear scans use a sensitive camera to track a small amount of radioactive material (radioisotope) that is given to the patient by mouth or through a vein. The scan may show abnormal areas of tissue in the bones, liver, spleen, kidney, brain, thyroid, or spine.\n  2. Magnetic resonance imaging (MRI) uses a magnetic field and radio waves to examine small sections of body organs and tissues.\n  3. Computerized tomography (CT) uses x-rays and can be done from different angles to provide a 3-dimensional view of tissues and organs.\n  4. Positron emission tomography (PET) uses a fluid with a radioisotope attached to it to show cellular activity in specific tissues. The fluid is given through a vein and travels to the cells that are most active (like cancer cells), showing if there is an actively growing tumor.\n* Pulmonary (lung) function tests: The patient breathes into a machine that measures the volume of air the person can move into and out of the lungs.\n* Heart function tests may include the following:\n\n  1. Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on the chest transmit information from the heart to a machine.\n  2. Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the heart and examine the function of the heart chambers and valves.\n  3. Multiple gated acquisition scan (MUGA) is a nuclear medicine test that uses a small amount of radioactive chemical injected into a vein. A special scanner creates an image of the heart for examining the beating motion of the muscle.\n\nDisease relapse or progression, or transplant-related problems may be treated with standard medical, radiation, or surgical therapy, or patients may be offered experimental therapy.",[26,27,28],"Graft-versus-leukemia","Graft vs Host Disease","Graft Rejection",[30,31,32,33,34,35],"Peripheral Blood Stem Cells","Graft Versus Leukemia\u002FMyeloma","Graft Versus Host Disease","Whole Body Irradiation","Leukemic Relapse","Natural History","RECRUITING","2026-06-03",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":40},"2005-04-22",{"name":44,"class":45},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100588311","optimal-adult-heart-transplant-immunosuppression-with-microrna-levels-100588311","NCT06939751","OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels","OPTIMAL","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Receipt of orthotopic heart transplant (OHT) within the prior 1 month ± 2 weeks\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Patient able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability (e.g., inotrope or vasopressor therapy)\n* Ongoing need for renal replacement therapy and\u002For dialysis\n* Active infection requiring either a) hospitalization b) treatment with antimicrobial therapy or c) reduction in immunosuppression\n* Active rejection being treated with intravenous medications or plasmapheresis","18 Years","99 Years",{"count":57,"type":22},250,"3 Years","This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[61,28],"Cardiac Failure","2026-04-20",{"date":64,"type":40},"2026-04-22",{"date":66,"type":40},"2025-10-28",{"date":68,"type":22},"2032-01-01",{"name":70,"class":71},"Inova Health Care Services","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":5},"100557036","optimal-pediatric-heart-transplant-immunosuppression-with-micrornas-100557036","NCT06532890","Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs","OPTIMA","Inclusion Criteria:\n\n* Age ≤ 18 years at time of transplant listing\n* Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment.\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability after transplant\n* Active infection requiring either a) hospitalization or b) treatment with antimicrobial drugs (does not include prophylaxis for infection or suppressive antibiotics given after transplant)\n* History of treated rejection prior to study enrollment\n* Inability to collect specified blood volume after enrollment and prior to 50 days post-transplant",{"count":80,"type":22},150,"This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[61,28],"2026-03-24",{"date":85,"type":40},"2026-03-25",{"date":87,"type":40},"2025-02-06",{"date":89,"type":22},"2029-10-01",{"name":70,"class":71},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100591590","zeroheart-biopsy---prediction-of-deceased-donor-heart-transplant-performance-from-organ-donors-using-pre-transplant-biopsies---a-pilot-study-100591590","NCT06982404","ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study","ZeroHeart","Inclusion Criteria:\n\nAll hearts from standard and expanded criteria donors as well as donor hearts from Donation after circulatory death (DCD) undergoing a heart biopsy at pre-implantation (at procurement) will be included. Consent will be obtained from the recipient at the time of transplant listing.\n\nExclusion Criteria:\n\nHearts will be excluded from the study if the participating clinician decides to discard the organ before transplantation or the recipient declines that the biopsy will be performed at the organ procurement.",{"count":99,"type":22},50,"The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal (\"Time Zero\") can help predict the future function and rejection risk of the transplanted heart in adult transplant recipients.\n\nThe main questions it aims to answer are:\n\n* Can early molecular injury in the donor heart, caused by brain death or circulatory death, be detected at the time of organ removal?\n* Can these early molecular findings predict short-, mid-, and long-term transplant outcomes, such as graft function or rejection?\n\nParticipants will:\n\n* Include heart donors whose hearts are being transplanted (both standard and marginal donors, including DBD and DCD cases)\n* Provide two small biopsies from the donor heart at the time of organ removal: one for routine pathology, one for microarray-based molecular analysis\n* Have routine follow-up biopsies after transplantation as part of standard care (no additional procedures required beyond medical standard)\n\nResearchers will compare biopsy results from different donor types (standard vs. marginal, DBD vs. DCD) to see if early molecular signals are linked to later heart transplant outcomes.",[102,28,103,104,105,106],"Heart Transplantation","Myocardial Injury","Organ Preservation","Biopsy","Gene Expression Profiling","2025-05-13",{"date":109,"type":40},"2025-05-21",{"date":111,"type":40},"2025-05-12",{"date":113,"type":22},"2028-05-31",{"name":115,"class":71},"Medical University of Vienna",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100464874","morphee--mechanisms-of-cell-death-induced-by-extracorporeal-photochemotherapy-100464874","NCT05333367","MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy","MORPHEE","Inclusion Criteria:\n\n* Adult patients\n* Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma\n\nExclusion Criteria:\n\n* Subjects with limited legal capacity.\n* Subjects judged by the investigator to be unlikely to comply with study procedures\n* Subjects with no social security coverage.\n* Pregnant women.\n* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.","85 Years",{"count":125,"type":22},20,"INTERVENTIONAL",[128],"NA","The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.",[131,132,28],"Cutaneous T-Cell Lymphoma","Graft Vs Host Disease",[134,135],"Cell death","Extracorporeal Photochemotherapy","2024-11-19",{"date":138,"type":40},"2024-11-21",{"date":140,"type":40},"2022-04-15",{"date":142,"type":22},"2025-07",{"name":144,"class":71},"Centre Hospitalier Universitaire de Besancon",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":126,"phases":154,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100568090","phase-4-study-to-compare-the-outcome-of-receiving-continued-immunosuppression-versus-stopping-immunosuppression-at-6-months-to-safely-prevent-human-leukocyte-antigen-hla-sensitization-in-patients-with-late-renal-graft-failure-100568090","NCT06676696","Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","Inclusion Criteria:\n\n* Patient must be able to understand and provide written informed consent\n* Patients older than 18 years who had received at least one previous renal transplant\n* Patients with a retained kidney graft failed for any reason which survived at least 3 months\n* Patients on dialysis, either hemodialysis or peritoneal dialysis. Patients can be on dialysis for a maximum of 6 months at the time of randomization, as long as the patients have taken an uninterrupted immunosuppressive regimen of calcineurin inhibitors (tacrolimus or cyclosporine) and steroids since dialysis was restarted\n* Patients already relisted or candidates to relist to deceased donor kidney transplantation according to the treating physician criteria\n* Patients taking immunosuppressants tacrolimus or cyclosporine\n* cPRA at the time of randomization ≤ 90%\n\nExclusion Criteria:\n\n* Patients who have received another solid organ transplantation (liver, lung, heart or pancreas)\n* Patients waiting for a living related \u002F unrelated kidney transplant\n* Graft survival of the failed graft lower than 3 months\n* Patients in dialysis more than 6 months at the time of randomization\n* Patients not accomplishing criteria to relist in the transplantation list according to the treating physician criteria\n* Pregnant women\n* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Patients should use one of the acceptable birth control measures recommended in the document \"Recommendations related to contraception and pregnancy testing in clinical trials\" published by the Clinical Trials Facilitation and Coordination Group (CTFG) (version 1.1, published 21\u002F09\u002F2020). Recommended birth control measures include oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, or sexual abstinence. If sexually active, the subject must have been using one of the accepted birth control methods at least one month prior to study entry.",{"count":153,"type":22},202,[155],"PHASE4","The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (\\> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months.\n\nThe main question this study aims to answer is:\n\nDoes maintaining long-term immunosuppression in patients with a late renal graft failure (\\> 3 months) safely reduce the risk of HLA sensitization?\n\nTo answer this question, patients will be assigned to a control arm or investigational arm:\n\n* Patients assigned to the control arm will receive standard treatment, in which immunosuppressant treatment is withdrawn after 6 months.\n* Patients assigned to the investigatonal arm will continue immunosuppressant treatment at low doses for 2 years.\n\nPatients recruited in this clinical trial will be followed for up to 2 years. During this time, patients will visit the clinic every 3 months for checkups and tests.",[158,159,28,160,161],"Renal Failure , Chronic","Graft Failure","Allograft","Renal Failure Chronic Requiring Dialysis",[163,164,165,166,167],"Renal failure","immunosuppressor","HLA sensitization","Graft failure","Calcineurin inhibitors","2024-11-05",{"date":170,"type":40},"2024-11-06",{"date":172,"type":40},"2024-01-22",{"date":174,"type":22},"2028-01-31",{"name":176,"class":71},"Hospital Universitari Vall d'Hebron Research Institute",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100375138","study-of-the-pathogenicity-and-humoral-immune-response-induced-by-bk-virus-in-lung-transplant-recipients-100375138","NCT04164576","Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients","BKV-Pneumo","Inclusion criteria:\n\n* Lung transplant recipients in Strasbourg University Hospital between 30 June 2018 and 31 December 2022\n* Male or female patients, age over 18 years\n* Patient having provided informed written consent to take part in the study\n* Patient affiliated to Social Security\n\nExclusion criteria:\n\n* Patient deprived of liberty, by judicial or administrative decision\n* Patient under legal guardianship\n* Impossibility to give complete information about this study to the patient",{"count":185,"type":22},120,"BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. The disruption of the balance between BKV replication and immune control is considered the key element in the development of these pathologies. During lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as EBV, CMV and probably BKV. Although the data on EBV and CMV reactivation are very clear and allow optimal management, the prevalence of BKV replication and its clinical impact in lung transplant recipients remains unknown at this time.\n\nThe aim of this study is to know the incidence and clinical impact of BKV replication in lung transplant recipients. Moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against BKV. The results could possibly enable to define predictive markers of BKV replication and of its evolution.",[188,28,189],"Renal-urinary Impairment","Infection Episodes",[191,192,193,194],"Lung transplantation","BKV","Nephropathy","Immunosuppression","NOT_YET_RECRUITING","2019-11-12",{"date":198,"type":40},"2019-11-15",{"date":200,"type":22},"2020-01",{"date":202,"type":22},"2027-06",{"name":204,"class":71},"University Hospital, Strasbourg, France"]